AACR 2024 | Novel immunotherapeutic approaches to treat patients with melanoma

Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the emerging efficacy and clinical translation of tumor-infiltrating lymphocyte (TIL) therapeutic lifileucel. Outlining the current clinical approval status of lifileucel, Prof. Gebhardt notes that a planned Phase III trial combining anti PD-1 monotherapy pembrolizumab and lifileucel may hold promise as a first-line treatment for patients with metastatic melanoma. Although the selection criteria and markers are not yet characterized, TIL therapy may be particularly beneficial to a selected group of patients with melanoma. Prof. Gebhardt additionally highlights TCR-engineered T cell therapies and bi-specific immunotherapies are also being developed. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.